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Strengthening the Role of Patent and Proprietary
Medicine Vendors in the Provision of Injectable
Contraception in Nigeria

AC T I V IT Y BR I E F

Nigeria is Africa’s most
populous nation, with
approximately 189
million people. Modern
contraceptive services are
underutilized in Nigeria,
which has a modern
contraceptive prevalence
rate (mCPR) of 10 percent.
The country’s low mCPR
highlights the need for
innovative programs to
increase women’s access to
contraceptive services.

In Nigeria, overall modern contraceptive use is very low, with just 10 percent
of currently married women using a modern method. However, 60 percent of
modern contraceptive services are obtained from private providers, including
Patent and Proprietary Medicine (PPM) shops, which provide more than half of
these private sector services. PPM shops are owned by Patent and Proprietary
Medicine Vendors (PPMVs) licensed to sell patent or proprietary drugs. PPMVs
sell a range of contraceptives including condoms, emergency contraceptive pills,
refills of oral contraceptive pills, and intrauterine devices (with a referral).
Injectable contraception is the most popular modern method in Nigeria, used by
more than 30 percent of currently married modern contraceptive users. Current
regulations do not permit PPMVs to sell or administer injectable contraceptives
because they are not regarded as sufficiently trained to initiate hormonal
contraceptives or to provide any type of injection. Instead, they can only refer
clients to health facilities. Nevertheless, almost 13 percent of injectables are
provided by PPM shops, according to the 2013 DHS.
Given this, it is an opportune time to generate evidence that can drive policy action
to formally engage and train PPMVs in the provision of high quality progestin-only
injectable contraceptive services as a key strategy to increase women’s access
to contraception.

STUDY OBJECTIVES
The Evidence Project, in collaboration with the Federal Ministry of Health (FMOH),
is conducting implementation research to:
1. Demonstrate the feasibility of PPMVs administering all forms of progestin-only
injectable contraceptives, such as Depo Provera and Sayana® Press.
2. Understand women’s experiences using progestin-only injectable
contraceptives, including the quality of care they receive when accessing
services from PPMVs.
The FMOH also asked the Evidence Project to develop and coordinate training
of PPMVs so that they have the necessary skills and information to sell, counsel,
and refer for all contraceptive methods, as well as administer progestin-only
injectable contraceptives.
The study is taking place in two phases. Phase one (November 2015 to December
2016) was carried out in two states representing two geopolitical zones: Oyo in
the south-west and Nasarawa in north-central Nigeria. In each state, four Local
Government Areas (LGAs) were selected as study sites (two urban and two rural)
for a total of eight LGAs. Phase two began in May 2017 at the request of and with
funding from USAID/Nigeria to generate similar evidence from states, selected
in consultation with local stakeholders, in the remaining four geopolitical zones,
so that the evidence is nationally representative. The phase two study states
include: Kaduna (north-west region), Ebonyi (south-east region), Cross River
(south-south region), and Bauchi (north-east region).

Injectable Contraceptive Methods
There are two types of injectable hormonal contraceptives:
those that are injected intramuscularly, like Depo Provera,
and those that are injected subcutaneously, like Sayana®
Press. In Nigeria, intramuscular injections were the only
available option for women wishing to use injectable contraception until 2014, when Sayana® Press was introduced
as a second safe and efficacious option. Sayana® Press
comes as a single dose in a prefilled, sterile syringe, and
is administered once every three months. It is packaged in
the Uniject injection system with an autodisposable device
that eliminates the need to prepare a needle and syringe.
Because the injection is subcutaneous, the needle is smaller and thus less painful.

THE PILOT INTERVENTION
PPMVs who participate in the study take part in a five-day
training on FP counseling for all methods and on administration
of progestin-only injectable contraceptives. The training covers
screening and counseling clients interested in the injectable;
intramuscular and subcutaneous injectable contraceptives
and their administration; safe storage and proper disposal;
reinjection procedures and instructions for clients , and what
to do if an adverse event occurs.
The research team has established new and strengthened
existing relationships with many stakeholders, including the
National Association of Patent and Proprietary Medicine Dealers
(NAPPMED), which helped recruit PPMVs for phase one of the
study, and the Pharmacy Council of Nigeria for phase two PPMVs.
Other stakeholders include the FMOH and state Ministries of
Health (SMOH) and implementing organizations that work with
PPMVs, who review and refine training materials, participate
in the training, and interpret the study’s findings. The team is
working with local government health facilities in study LGAs
to ensure the acceptance of referrals by PPMVs. Additionally,
FMOH, SMOH, and LGA officials are involved in the planning,
implementation, and training of PPMVs. The Society for Family
Health (SFH) and DKT will be involved to reduce the likelihood
of stock-outs of Depo Provera and Sayana® Press and ensure
the availability of quality products. SFH and DKT are two of the
main sources for private providers to purchase affordable family
planning commodities in the private sector in Nigeria.

HOW THE DATA ARE BEING COLLECTED
Pre- and post-PPMV training surveys
The PPMVs complete pre- and post-training surveys to
ascertain changes in knowledge and practices related to
injectable contraceptives. Additionally, follow-up surveys are
administered three, and nine months post-training to assess
the PPMVs’ practices, knowledge and skills over time.

Monitoring/supervision of PPMVs
Teams of study investigators, FMOH, SMOH, LGA officials
and PCN monitor activities of trained PPMVs through followup meetings to identify and resolve implementation issues.
The monitoring visits will track progress, challenges, and
successes of implementation, as well as gather information
on clients’ experience of adverse events. Involvement of the
ministry stakeholders will also help them to see firsthand
the PPMVs’ abilities with administration of injectables and
potentially help with eventual policy change.

Client exit interviews and surveys
To obtain female clients’ perspectives, the researchers conduct
exit interviews with progestin-only injectable contraceptive
users who receive services from trained PPMVs. These users
are also contacted for surveys at three, six, and nine months
after their initial visit, enabling the assessment of continuation
rates of progestin-only injectable contraceptive methods.

FOSTERING RESEARCH UTILIZATION
The research team has from the beginning of the study
and will continue to engage key decision makers, such as
the FMOH, SMOH and LGA health officials; utilize technical
working groups to discuss emerging findings and lessons as
the study progresses; and identify champions to promote the
study findings to key stakeholders, such as health officials,
NAPPMED, Pharmacy Council of Nigeria, FMOH, donors, NGOs,
and so forth. In addition to regular meetings throughout the
study to keep stakeholders informed of the progress and initial
findings, a national dissemination meeting will be held with the
key stakeholders to review and interpret the results and identify
how they can be translated into policy. State-level meetings
also will be held to share implementation successes and
challenges related to PPMV delivery of injectable contraceptive
services.
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